Next Article in Journal
Blue Light Damage and p53: Unravelling the Role of p53 in Oxidative-Stress-Induced Retinal Apoptosis
Next Article in Special Issue
Melatonin Prevents Alcohol- and Metabolic Dysfunction- Associated Steatotic Liver Disease by Mitigating Gut Dysbiosis, Intestinal Barrier Dysfunction, and Endotoxemia
Previous Article in Journal
An Effective, Green Synthesis Procedure for Obtaining Coumarin–Hydroxybenzohydrazide Derivatives and Assessment of Their Antioxidant Activity and Redox Status
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antioxidants
Volume 12
Issue 12
10.3390/antiox12122071
antioxidants-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Antioxidant Properties of Salvia verbenaca Extract Contribute to Its Intestinal Antiinflammatory Effects in Experimental Colitis in Rats

by
Teresa Vezza
1,2,3,†,
Jose Alberto Molina-Tijeras
1,2,†,
Alba Rodríguez-Nogales
1,2,*,
Jose Garrido-Mesa
1,
María de la Luz Cádiz-Gurrea
4,
Antonio Segura-Carretero
4,
María Reyes González-Tejero
5,
María Elena Rodríguez-Cabezas
1,2,*,
Julio Gálvez
1,2,6,‡ and
Francesca Algieri
1,2,‡
1
Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain
2
Instituto de Investigación Biosanitaria de Granada (ibs. GRANADA), 18012 Granada, Spain
3
Servicio de Digestivo, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain
4
Department of Analytical Chemistry, Faculty of Science, University of Granada, 18071 Granada, Spain
5
Department of Botany, University of Granada, 18071 Granada, Spain
6
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
‡
These authors contributed equally to this work.
Antioxidants 2023, 12(12), 2071; https://doi.org/10.3390/antiox12122071
Submission received: 24 October 2023 / Revised: 25 November 2023 / Accepted: 30 November 2023 / Published: 2 December 2023
(This article belongs to the Special Issue Significance of Antioxidant Mechanisms in Intestinal Inflammation)
Browse Figures
Versions Notes

Abstract

:
Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammation with unpredictable symptom fluctuations. While there is no effective cure for IBD, various treatments aim to manage symptoms and improve the quality of life for affected individuals. In recent years, there has been growing interest in the potential benefits of certain natural plants and herbs in the management of IBD. In this regard, this study aimed to evaluate the immunomodulatory and anti-inflammatory effects of a well-characterized extract of Salvia verbenaca (S. verbenaca) in an experimental model of colitis in rats. Interestingly, the daily administration of S. verbenaca (10 and 25 mg/kg) effectively alleviated colitis symptoms, as evidenced by reduced weight/length ratio and colonic damage. Moreover, it reduced oxidative stress markers (MPO and GSH), decreased pro-inflammatory cytokine expression (Il-6, Il-12a, Il-1β, Il-23, Icam-1, Mcp-1, Cinc-1), and preserved the integrity of the intestinal barrier (Villin, Muc-2, Muc-3). These effects suggest S. verbenaca extract could represent a potential complementary candidate to treat gastrointestinal disorders. Its beneficial actions can be related to its antioxidant properties as well as the downregulation of the immune response, which can result in the improvement in the intestine epithelial barrier.

Graphical Abstract

1. Introduction

Inflammatory bowel disease (IBD), which mainly encompasses ulcerative colitis (UC) and Crohn’s disease (CD), refers to idiopathic disorders characterized by spontaneous and chronic relapsing inflammation of the gastrointestinal tract. Although its clinical course is largely unpredictable, IBD is characterized by the existence of alternative periods of exacerbation and remission in the symptoms, which include diarrhea, vomiting, rectal bleeding, and abdominal cramps/discomfort, thus reflecting a situation of epithelial barrier disruption and mucosal ulceration [1,2]. Its etiology is still unclear, although many studies have proposed a prominent role of gut luminal bacteria together with an impaired intestinal barrier function. This triggers an abnormal immune response in IBD patients, thus contributing to the initiation and progression of these intestinal conditions [3]. The altered immune response encompasses the activation of different immune cells (monocytes, neutrophils, T lymphocytes, or macrophages) with overexpression and release of pro-inflammatory mediators, including cytokines such as interleukin (IL)-6, IL-1 β, and tumor necrosis factor-alpha (TNF-α), as well as activated reactive oxygen and nitrogen species, which play a critical role in the development of IBD [4].
As there is currently no specific curative treatment for human IBD, different drugs are currently used to target multiple stages of the inflammatory cascade, mainly by using immunosuppressants, glucocorticoids or aminosalicylates, and, more recently, biological agents [5,6]. However, these drugs exhibit limited efficacy for long-term remission and are linked to significant side effects [7]. For this reason, there is a clear demand for new strategies combining efficacy and safety for therapeutic IBD management.
Natural products have a prominent role as a source of therapeutic agents, especially those from medicinal plants [8,9,10]. Among the Mediterranean area, traditionally recognized as an important source of herbal medicine, Salvia seems to be the most interesting. It constitutes an important genus of the Lamiaceae family, reputed for its medicinal properties and used in human nutrition and health, particularly in coronary heart diseases and hypertension [11], hepatocirrhosis [12], chronic renal failure [13], and inflammatory disorders [14,15]. Polyphenolic compounds are thought to be responsible, at least in part, for their health effects, but their mechanisms of action and benefit for IBD remain unexplored. For all these reasons, we evaluated the immunomodulatory and anti-inflammatory effects of S. verbenaca extract in an acute 2,4,6-Trinitrobenzene Sulfonic Acid (TNBS)-induced experimental colitis, a model that mimics several features of human IBD [16]. We assessed the inflammatory response by determining inflammatory markers such as myeloperoxidase (MPO) activity and cytokines profile. Furthermore, immunomodulatory effects of the extract (0.1–100 μg/mL) were investigated in murine (CMT-93) epithelial cells.

2. Materials and Methods

2.1. Chemicals and Reagents

The analytical procedures were performed using LC-MS-grade formic acid, acetonitrile, and water for HPLC platforms, which were purchased from Fluka (Sigma-Aldrich, Steinheim, Germany) and Lab-Scan (Gliwice, Sowinskiego, Poland), respectively. For solutions, Milli-Q Milli-pore ultrapure water (Bedford, MA, USA) and methanol VWR Chemicals (Radnor, PA, USA) were used.
For antioxidant capacity assays, the following reagents were provided from the indicated suppliers: hydrochloric acid, sodium hydroxide, TPTZ (2,4,6-tris(2-pyridyl)-s-triazine), acetic acid, and sodium carbonate were acquired from Fluka (Honeywell, NC, USA). Sodium phosphate monobasic and dibasic, AAPH (2,2′-azobis(2-amidinopropane) dihydrochloride), fluorescein, heptahydrate ferrous sulfate, ferric chloride, sodium acetate, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), potassium persulfate, ABTS (2,2′-azinobis (3-ethylbenzothiazoline-6-sulphonate)), Folin reagent, and gallic acid were obtained from Sigma-Aldrich (St. Louis, MO, USA). Absolute ethanol was purchased from Riedel-de-Haën (Honeywell, NC, USA). All chemicals, unless otherwise indicated, were purchased from Sigma-Aldrich (Merck Life Science S.L.U., Madrid, Spain).

2.2. Plant Material and Preparation of the Extract

Fresh, native S. verbenaca plants were collected from urban fields in Granada, Spain (37.19280, −3.599) in April 2016 and authenticated by taxonomist Dr. M.R. González-Tejero, senior researcher of the Botany Department of the University of Granada, Spain. A voucher specimen (No. 62623-1) was deposited in the herbarium of the University of Granada (Granada, Spain).
The plant extract was prepared as follows: 5 g of ground plant material was mixed with washed sea sand (Panreac Quımica S.A.U., Castellar del Vallés, Spain) and extracted with 30 mL of methanol 50% (v/v) at 1500 PSI and 80 °C for 10 min in a Dionex ASE200 extraction system (Dionex Corporation, Sunnyvale, CA, USA); this method was already described by Delgado-Torre et al., 2012 [17]. Liquid extract was pooled, and the solvent evaporated under vacuum at 60 °C after two cycles of extraction. Then, land dry extract was stored at −20 °C. Extraction efficiency was 37.64% (w/w).

2.3. Chemical Composition of S. verbenaca Using High-Performance Liquid Chromatography-Mass Spectrometry Condition

For the phytochemical characterization of S. verbenaca extract, HPLC-ESI-QTOF analysis was carried out. Firstly, the extract was reconstituted to a concentration of 5 mg/mL in methanol:water (20:80; v:v). The solution was then vortexed, filtered (0.2 µm), and transferred to an HPLC vial for analysis. In addition, blank samples were prepared to detect contaminants. An HPLC 1290 system coupled to a quadrupole time-of-flight (QTOF) mass spectrometer (G6530C UHD, Agilent Tech., Santa Clara, CA, USA) equipped with a Jet Stream dual ESI interface was used. Chromatographic separation was performed on an analytical C18 column (ACQUITY UPLC BEH Shield RP18 Column, 130 Å, 1.7 µm, 2.1 mm × 150 mm). The mobile phases A and B were acidified water with 0.1% v/v formic acid and acetonitrile, respectively. The following linear elution gradient was used: 0 min, 100% A; 5 min, 90% A; 18 min 15% A; 24 min, 0% A; 25.50 min, 0% A; 26.50 min, 95% A; 32.50 min, 95% A. The flow rate and the injection volume were 0.4 mL/min and 5 μL, respectively. The MS acquisitions were performed in negative ionization mode and full scan mode (mass-to-charge ratio from 50 to 1200 m/z). Moreover, the sample was also analyzed in a DDA MS/MS acquisition mode using fixed collision energies of 10.00, 30.00, 60.00 eV. The source parameters were nebulization gas pressure 2 bar, nozzle voltage 500 V, capillary voltage 4 kV, desolvation temperature 350 °C, nebulizer 20 psig, desolvation gas flow resolution 10 L/min, gas temperature 200 °C, and scan duration 1.2 s. The MS raw data were firstly transformed using the MSConverGUI software (https://proteowizard.sourceforge.io/download.html) (accessed on 23 June 2023) and then processed through the open-source software MZmine 2.53. The information obtained was compared with the existing literature to annotate the compounds.

2.4. Total Phenolic Content and Antioxidant Capacity Assays

Total phenolic content (TPC) and antioxidant capacity assays were carried out by Folin–Ciocalteu (TPC), FRAP, TEAC, and ORAC, respectively. All assays were performed on a Synergy H1 Monochromator-Based Multi-Mode Microplate reader (Bio-Tek Instruments Inc., Winooski, VT, USA) in accordance with the methodology previously reported [18]. All measurements were made in triplicate.
Moreover, the 2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity of the extract was assessed spectrophotometrically in an MRX+ tc (DYNEX Technologies GmbH, Denkendorf, Germany) by monitoring the disappearance of PPH· at 515 nm, according to a previously described method [19]. The antioxidant activity was expressed as half-maximal inhibitory concentration (IC50) value (in μg/mL), which was obtained by a non-linear regression with a one-phase exponential association equation using GraphPad Prism version 9.0 (GraphPad Software, La Jolla, CA, USA). The antiradical activity was also compared to well-known antioxidants, such as gallic and ascorbic acid.

2.5. In Vitro Studies

Murine colonic epithelial CMT-93 cells obtained from the Cell Culture Unit of the University of Granada (Granada, Spain) were maintained in RPMI Medium supplemented with streptomycin (1 mg/mL), penicillin (100 units/mL), L-glutamine (2 mmol/L), and 10% heat-inactivated fetal bovine serum in a humidified 5% CO2 atmosphere at 37%. Cells were seeded into 96-well plates at a density of 5 × 105 cells/well, grown until the formation of a monolayer, pre-incubated with different concentrations of the extract ranging from 0.1 to 100 μg/mL for 2 h, and subsequently stimulated with Escherichia coli 055:B5 lipopolysaccharide (LPS) at a concentration of 10 μg/mL for 72 h.
LPS-stimulated cells and untreated unstimulated cells were used as positive and negative controls, respectively. After 72 h, measurements of cytokines in cell culture supernatants were assayed by sensitive enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Inc., Minneapolis, MN, USA) following the manufacturer’s instructions.
Finally, the CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) was employed to analyze the effect of the extract on cell viability. Briefly, a small amount of the [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium solution was added directly to culture wells and incubated for 1–4 h. The cell culture medium’s absorbance was recorded at 490 nm on an MRX Dynex microplate reader (Dynex Technologies, Chantilly, VA, USA). The cellular viability was determined based on the average absorbance values and compared with those of the untreated control cells. The same experimental design was performed to analyze the RNA expression of various inflammatory mediators. In this case, 2 h after the stimulation with LPS, supernatants were removed, and the cells were collected for RNA extraction.

2.6. Animals and Experimental Design

The study was performed in rigorous accordance with the “Guide for the Care and Use of Laboratory Animals” as declared by the US National Institutes of Health (NIH), and all protocols were approved by the Ethics Committee of Laboratory Animals of the University of Granada (Spain) (reference number CEEA-2010-286). Female Wistar rats (180–200 g) derived from Janvier Labs (St Berthevin, France) were housed in Makrolon® cages, kept at constant room temperature, relative humidity (50–80%), and illumination (12/12 h light–dark cycle), and were given unrestricted access to tap water and food. The animals were randomly assigned to five groups (n = 10). Three of them received daily either the corresponding dose of the extract S. verbenaca (10 and 25 mg/kg) or dexamethasone (1.2 mg/kg), a synthetic glucocorticoid used as a positive control. Both the extract and dexamethasone were suspended in 1 mL of carboxymethylcellulose and administered by oral gavage. A non-colitic (NC) group and an untreated TNBS control group were also included as reference. These groups received only the vehicle used for administering the test compounds. Colitis was induced in both control and treated groups as indicated in previous reports [20]. In summary, rats underwent an overnight fasting period, were deeply anesthetized using isoflurane (Isoflo®, Esteve, Barcelona, Spain), and were administered 10 mg of TNBS dissolved in 0.25 mL of 50% ethanol (v/v), which was instilled into the colon by using a Teflon cannula inserted 8 cm through the anus. Animals were kept in a head-down position until they gradually recovered from anesthesia, after which they were then returned to their home cages. The remaining animals underwent intracolonic administration of phosphate-buffered saline (0.25 mL) instead of TNBS. Treatments described were administered starting the same day of colitis induction until the day before rats’ sacrifice, which took place 8 days after the induction of the colonic damage. Water and food intake, occurrence of diarrhea, and animal body weights were monitored daily throughout the entire experiment. After mask inhalation of isoflurane, animals were sacrificed.
Then, the colonic segment was collected aseptically, placed on an ice-cooled plate, longitudinally opened, and thoroughly rinsed to remove its luminal contents with ice-cold saline solution. Subsequently, each specimen was weighed, and its length measured. Colonic damage score (0–10 scale) (Table 1) was macroscopically examined by two independent observers, according to previously reported procedures [20].
Subsequently, the collected colonic samples were divided into various longitudinal fragments for biochemical determinations or RNA isolation. Interestingly, the activity of a specific marker of neutrophil infiltration, known as myeloperoxidase (MPO), was assayed in colon homogenates according to the procedures described by Krawisz et al. [21], and the results were expressed as MPO units per gram of wet tissue; one unit of MPO activity was defined as the amount needed to degrade 1 µmol hydrogen peroxide per minute at 25 °C. Similarly, the quantitative measurement of total glutathione content was determined with the enzymatic recycling assay reported by Anderson et al. [22], and the results were expressed as nmol/g wet tissue.

2.7. Analysis of Gene Expression by RT-qPCR

Total RNA (from colon or cells) was isolated following the standard Tri-Reagent® protocol and quantified using the Thermo Scientific NanoDrop™ 2000 Spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). Afterwards, 2 μg of RNA was reverse transcribed using oligo(dT) primers (Promega, Southampton, UK). Real-time quantitative PCR amplification and detection was performed on optical-grade 48-well plates in an EcoTM Real-Time PCR System (Illumina, San Diego, CA, USA) with 20 ng of cDNA, the KAPA SYBR® FAST qPCR Master Mix (Kapa Biosystems, Inc., Wilmington, MA, USA), and specific primers at their annealing temperature (Ta) (Table 2). The expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (Gapdh) was used to normalize (m)RNA expression. The relative changes in gene expression were calculated using the ∆∆Ct method [23].

2.8. Statistics

All results are expressed as the mean ± SEM. Differences between means were tested for statistical significance using a one-way analysis of variance (ANOVA) and post hoc least significance tests. Non-parametric data (score) are expressed as the median (range) and were analyzed using the Kruskal–Wallis test. All statistical analyses were performed with GraphPad Prism version 9.0 (GraphPad Software Inc., La Jolla, CA, USA) with statistical significance set at p < 0.05.

3. Results

3.1. Chemical Characterization of S. verbenaca

The UHPLC-MS was used for a comprehensive characterization of the chemical composition of S. verbenaca extract, and Figure 1 shows its base peak chromatogram (BPC). Identified compounds are included in Table 3, numbered per elution order, and indicate their retention times (RT), experimental m/z, molecular formula, and proposed compounds. A total of 80 compounds were detected, mainly caffeic acid derivatives and flavonoids.

3.2. Antioxidant Capacity of S. verbenaca

The total phenolic content (TPC) of S. verbenaca was determined using the Folin–Ciocalteu method, which was 166 ± 4 mg GAE/g of plant extract. Subsequently, the antioxidant potential of this extract was confirmed by FRAP, ORAC, and TEAC assays (Table 4). These assays collectively indicated significant free radical scavenging activity in S. verbenaca. Additionally, the extract showed an antiradical effect in the DPPH assay, with an IC50 of 59.9 ± 8.7 μg/mL.

3.3. Immunomodulatory Properties of S. verbenaca in Murine Intestinal Epithelial Cells

The beneficial effects of S. verbenaca extract were evaluated in murine intestinal epithelial cells (CMT-93). Incubation of cells with different concentrations of the extracts (0.1–100 μg/mL) did not affect cell viability and did not induce any inflammatory response (Figure 2).
Stimulation of CMT-93 cells with LPS resulted in pro-inflammatory cytokine (IL-6 and TNF-α) expression and release, quantified by RT-qPCR and ELISA, respectively (Figure 3A). Both cytokines were significantly reduced by the different concentrations of the extract (Figure 3A; p < 0.05 vs. LPS).
Similarly, S. verbenaca inhibited the increased mRNA expression of Icam-1 and Mip-2 in these cells after LPS stimulation (p < 0.05 vs. LPS) (Figure 3B). Moreover, the expression of Muc-2, a secretory protein crucial for the maintenance of epithelial integrity, was reduced after LPS stimulation of the cells, and this effect was partially reversed with the different doses of the extract (p < 0.05 vs. LPS).

3.4. Intestinal Anti-Inflammatory Effect of S. verbenaca in TNBS-Induced Colitis in Rats

Experimental colitis was induced by the intrarectal application of TNBS to rats, a haptenizing agent that triggers an exacerbated immunological response associated with the development of the inflammatory process in the colon. During the experiment, colitic rats from the control group showed reduced food intake and body weight loss (Figure 4A), together with the presence of bloody diarrhea. Once the rats were sacrificed, macroscopic examination of the colonic specimens displayed signs indicative of acute inflammation and necrosis of the colonic tissue (Figure 4B). Additionally, adhesions to adjacent organs were observed.
In addition, the intestinal inflammatory process in the untreated control group was characterized by a marked increase in colonic weight/length ratio (a reliable indicator of tissue edema and inflammation) in comparison with non-colitic rats (Figure 4C). Administration of S. verbenaca extract, at doses of 10 and 25 mg/kg, significantly reduced the macroscopic damage score (p < 0.05), thus attenuating the severity and extension of the colonic injury (Figure 4C). Similarly, colitic rats receiving the extract showed a lower colonic weight/length ratio in comparison with untreated controls (Figure 4C). The administration of the glucocorticoid dexamethasone (1.2 mg/kg) to colitic rats also resulted in a significant amelioration of the weight/length ratio as well as in the colonic damage score when compared with untreated TNBS control animals (Figure 4C).
The intestinal anti-inflammatory effects of S. verbenaca were also supported by biochemical evidence. Thus, TNBS administration increased colonic MPO activity (Figure 4D), a reliable indicator of neutrophil infiltration in the inflamed intestine. Interestingly, and confirming the results obtained macroscopically, the S. verbenaca-treated group showed a decrease in colonic MPO activity, although this was statistically different only at the highest dose assayed in comparison to the untreated TNBS-control group (Figure 4D). Additionally, colonic inflammation-associated oxidative stress was evidenced by a reduced colonic glutathione content, a potent antioxidant peptide, which was markedly increased in colitic animals treated with the extract or dexamethasone (Figure 4D).
Likewise, colonic inflammatory status was also characterized by significant increased mRNA expression of various pro-inflammatory markers, including Il-1β, Il-6, Il-12a, and Il-23, in the colonic tissue from untreated TNBS colitic animals compared with non-colitic rats (Figure 5). The S. verbenaca-treated group showed a marked downregulation in the mRNA expression of Il-1β, Il-6, Il-12a and Il-23 (p < 0.05 vs. colitic control group), thus confirming the amelioration in the colonic inflammatory status exerted by the extract in this experimental model of colitis. Similarly, colitic rats treated with dexamethasone also displayed significantly reduced expression levels of all these cytokines (Figure 5).
In addition, the colonic inflammatory process was also characterized by the increased expression of the inducible enzyme iNos when compared to the untreated colitis control group. The administration of S. verbenaca extract (25 mg/kg) or dexamethasone to colitic rats significantly decreased the elevated colonic expression of iNos (Figure 6). This reduction may lead to a decreased production of nitric oxide (NO), potentially preventing the reported adverse effects associated with high NO production in the inflamed colonic tissue [24]. The colonic injury induced by TNBS administration was also evidenced by the increased expressions of the intercellular adhesion molecule-1 (Icam-1) as well as the chemokines monocyte chemotactic protein-1 (Mcp-1) and cytokine-induced neutrophil chemoattractant-1 (Cinc-1) (Figure 6). The expression of these markers was notably reduced by the administration of the extract of S. verbenaca, at both doses assayed, as well as by the glucocorticoid.
Similarly, when the colonic barrier integrity was evaluated in control colitic rats without treatment, an impaired colonic expression of the mucins Muc-2, Muc-3, and Villin was observed, indicating a defect in the colonic permeability (Figure 7). Of note, both the extract and dexamethasone significantly increased the expression of these mediators, thus resulting in the amelioration of the intestinal barrier dysfunction typically observed in colitic rats (Figure 7).

4. Discussion

Despite the largely unknown etiology of IBD, accumulated experimental and clinical data suggest that the altered immunological functions resulting from the interplay between genetic predisposition and certain environmental factors can facilitate the mucosal inflammation of the gastrointestinal tract in these chronic conditions [25,26].
Nowadays, many drugs used in IBD treatment have positive efficacy, but high price, inconvenient dosing regimen, as well as severity and frequency of adverse effects limit their long-term use [7,27]. For this reason, additional research approaches to IBD therapy are emerging. Among these, the use of alternative and/or complementary treatments, such as herbal remedies, is increasing constantly [28,29]. However, well planned scientific studies focusing on the safety or efficacy of these natural products are limited. With this purpose, the present study aimed to evaluate the immunomodulatory and anti-inflammatory effects of a well-characterized extract from S. verbenaca in the TNBS model of experimental rat colitis, which shows some resemblance to the main manifestations of human IBD [16]. Firstly, S. verbenaca administration to colitic rats significantly attenuated the symptoms that characterize the disease; both doses of the extract resulted in the reduction of body weight loss as well as the prevention of diarrhea and rectal bleeding. The beneficial effects of S. verbenaca were also shown macroscopically, with a decrease of mucosal edema and hemorrhagic ulcerations caused by TNBS instillation, and then confirmed biochemically, with an amelioration of several inflammatory markers implicated in the pathogenesis of IBD. Emerging evidence suggests oxidative stress as a main player in these inflammatory processes. Reactive oxygen species (ROS), derived from activated phagocytic cells and myeloperoxidase activity, are increased in both UC and CD. High ROS levels in mucosal cells participate in the induction of inflammatory and immune responses, which could directly or indirectly cause the gut mucosal barrier dysfunction that orchestrates the colitis process [30,31]. The treatment of colitic rats with the extract of S. verbenaca showed a partial inhibition of MPO activity in the inflamed colon compared to untreated colitic rats, suggesting its ability to reduce neutrophil infiltration into the colonic mucosa [32]. In this regard, the extract reduced the colonic expression of critical markers involved in chemotaxis, such as Cinc-1 and Mcp-1, thus collaborating in the attenuation of leukocyte infiltration into the tissue injury [33]. Moreover, the activation of innate and/or adaptive immune responses in IBD involves an increased expression of other mediators, including adhesion molecules [34]. Interestingly, treatment with S. verbenaca demonstrated the capacity to modify the increased expression of Icam-1 in both in vivo and in vitro experimental conditions. Moreover, the in vitro experiments conducted in the CMT-93 cell line showed that the extract was able to downregulate the expression of Mip-2, a chemokine that affects neutrophil recruitment and activation [35], thus justifying the results shown in vivo.
It is well known that neutrophils constitute an important source of free radicals, thus contributing to oxidative stress associated with the intestinal inflammatory process. The impact of the extract on neutrophil infiltration can account for reduced free radical production. Supporting this, the administration of the extract to colitic animals counteracted the depletion of the colonic glutathione, thus preserving the colonic tissue from the inflammation-derived oxidative damage in experimental colitis [36]. Moreover, the antioxidant properties ascribed to the extract of S. verbenaca and evidenced in the different in vitro assays in the present study can also ameliorate the oxidative stress in the inflamed colon, preserving it from the damage induced after TNBS colonic administration to rats.
Furthermore, the imbalance between pro-inflammatory and anti-inflammatory cytokines in the colonic tissue is crucial in the onset and perpetuation of the disease in intestinal inflammation [37]. Different studies have reported that inflamed colonic mucosa from CD and UC patients are characterized by the increased expression of pro-inflammatory cytokines such as Il-6, Il-1β, Il-12a, Il-23, and Tnf-α [38,39,40]. In the present study, the intestinal anti-inflammatory effect of S. verbenaca on TNBS-induced colitis was linked to a reduced expression of pro-inflammatory mediators. This gives evidence for the improvement of the altered colonic immune response that occurs in the TNBS-colitis model. Notably, the immunomodulatory properties of the extract were also revealed in vitro since it decreased the expression and/or release of key pro-inflammatory cytokines such as IL-6, and TNF-α in LPS-stimulated CMT-93 murine epithelial cells.
Overall, all these beneficial properties exhibited by the extract can be attributed to the presence of various bioactive compounds that can act simultaneously on different targets of the inflammatory response. Indeed, the results obtained by the DPPH assay revealed that the extract displays antioxidant properties (16.8%), probably correlated to its high content of caffeic acid and phenolic derivatives such as flavonoids. Of note, these bioactive compounds are potent antioxidants that present interesting anti-inflammatory activity [41,42]. In fact, in vitro and in vivo studies have demonstrated that salvianolic acid (another active constituent of S. verbenaca) can regulate the expression of antioxidant enzymes by scavenging oxygen free radicals, thus providing hydrogen atoms and reducing the production of oxygen-containing non-radicals and oxygen free radicals [43].
Similarly, caffeic acid derivatives can scavenge nitric oxide as well as modulate iNOS expression [41], while flavonoids can inhibit transcription factors or regulatory enzymes essential for controlling inflammatory mediators. Regarding the latter, previous studies have reported that flavonoids such as quercitrin, rutin, glabridin, naringenin, chrysin, and cardamonin can reduce the severity of experimental-induced colitis and ameliorate the histological damage by reducing cytokine release in the colonic tissue [44,45,46]. Some of the mechanisms proposed to support these beneficial effects have been related to its ability to inhibit cellular pathways, including nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and STAT activation [47,48,49], which actively contribute to the pathology of these intestinal conditions [50,51].
Moreover, many of these compounds have been also associated with the preservation of the epithelial barrier function [42,52]. It is well known that dysregulation of the epithelial barrier is a salient feature of IBD [53,54]. A defective epithelial barrier with compromised adherence and tight junctions can lead to an excessive access of luminal agents into the intestinal tissue, thus facilitating the induction of an exacerbated inflammatory response [55]. These changes also compromise epithelial barrier functions, which, if impaired, can cause inappropriate secretion of intestinal fluid and electrolytes, in association with a reduced intestinal absorptive capacity, thus resulting in abdominal cramps and diarrhea, frequently observed in IBD patients with active disease.
Phytochemical compounds such as naringenin [45] and salvianolic acid [56] have demonstrated their ability to enhance epithelial barrier permeability in colitis. This improvement was observed through the preservation of the intestinal tight junction barrier function and structure, both of which were found to be compromised after DSS administration. Similarly, in our study, TNBS-induced colitis resulted in a reduction in the expression of Muc-2 and Muc-3, which are key constituents of the colonic mucus layer [57,58], and villin, a bioactive peptide involved in epithelial repair and regeneration [59]. The administration of the extract significantly reversed the reduced expression of these proteins involved in maintaining an adequate colonic barrier function, thus preserving the mucus-secreting layer covering the epithelium and acting as a physical barrier against luminal content translocation. This beneficial effect can probably be also ascribed to the presence of flavonoids in the extract, given the reported ability to reduce intraluminal fluid accumulation, enhance intestinal motility, and inhibit muscle contractility, as evidenced in different experimental studies [60,61].

5. Conclusions

S. verbenaca exerted intestinal anti-inflammatory effects in the TNBS-induced colitis in rats. The antioxidant properties linked to its phenolic components seem to play a pivotal role. Additionally, other mechanisms can also mediate the observed beneficial effects in experimental colitis, including their capacity to downregulate the expression and production of various proinflammatory mediators, such as cytokines and chemokines, as well as to enhance intestinal barrier integrity. These results suggested that S. verbenaca extract may represent a potential complementary candidate in the management of gastrointestinal disorders.

Author Contributions

Conceptualization, T.V., J.A.M.-T., F.A. and J.G.; methodology, J.A.M.-T., A.R.-N., J.G.-M., M.E.R.-C., M.d.l.L.C.-G., M.R.G.-T. and A.S.-C.; data curation, J.A.M.-T., A.R.-N. and M.E.R.-C.; validation, T.V., F.A. and J.G.; writing—original draft preparation, T.V., J.A.M.-T. and F.A.; writing—review and editing, M.E.R.-C., A.R.-N., F.A. and J.G.; supervision and funding acquisition, F.A. and J.G. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Junta de Andalucia (AGR-6826 and CTS 164) and the Spanish Ministry of Economy and Competitivity (SAF2011-29648) and with funds from the European Union. The CIBER-EHD is funded by the Instituto de Salud Carlos III. J.A. Molina-Tijeras is the recipient of pFIS (FI20/00159), Instituto de Salud Carlos III; Programa de Doctorado Nutricion). T. Vezza is the recipient of Miguel Servet contract (CP22/00153) from the Instituto de Salud Carlos III.

Institutional Review Board Statement

This study was carried out in accordance with the ‘Guide of the Care and Use of Laboratory animals’ as promulgated by the National Institute of Health, and the protocols were approved by the Ethics Committee of Laboratory Animals of the University of Granada (Spain) (reference number CEEA-2010-286).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

The figures were created using Server Medical Art (https://smart.servier.com), accessed on 15 September 2023.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bruner, L.P.; White, A.M.; Proksell, S. Inflammatory Bowel Disease. Prim. Care 2023, 50, 411–427. [Google Scholar] [CrossRef]
  2. Zhang, Y.Z.; Li, Y.Y. Inflammatory bowel disease: Pathogenesis. World J. Gastroenterol. 2014, 20, 91–99. [Google Scholar] [CrossRef]
  3. Burisch, J. Crohn’s disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Dan. Med. J. 2014, 61, B4778. [Google Scholar] [PubMed]
  4. Guan, Q.; Zhang, J. Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease. Mediat. Inflamm. 2017, 2017, 4810258. [Google Scholar] [CrossRef]
  5. Elhag, D.A.; Kumar, M.; Saadaoui, M.; Akobeng, A.K.; Al-Mudahka, F.; Elawad, M.; Al Khodor, S. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. Int. J. Mol. Sci. 2022, 23, 6966. [Google Scholar] [CrossRef]
  6. Juillerat, P.; Grueber, M.M.; Ruetsch, R.; Santi, G.; Vuillemoz, M.; Michetti, P. Positioning biologics in the treatment of IBD: A practical guide—Which mechanism of action for whom? Curr. Res. Pharmacol. Drug Discov. 2022, 3, 100104. [Google Scholar] [CrossRef]
  7. Quezada, S.M.; McLean, L.P.; Cross, R.K. Adverse events in IBD therapy: The 2018 update. Expert Rev. Gastroenterol. Hepatol. 2018, 12, 1183–1191. [Google Scholar] [CrossRef] [PubMed]
  8. Holleran, G.; Scaldaferri, F.; Gasbarrini, A.; Curro, D. Herbal medicinal products for inflammatory bowel disease: A focus on those assessed in double-blind randomised controlled trials. Phytother. Res. 2020, 34, 77–93. [Google Scholar] [CrossRef]
  9. Algieri, F.; Rodriguez-Nogales, A.; Rodriguez-Cabezas, M.E.; Risco, S.; Ocete, M.A.; Galvez, J. Botanical Drugs as an Emerging Strategy in Inflammatory Bowel Disease: A Review. Mediat. Inflamm. 2015, 2015, 179616. [Google Scholar] [CrossRef] [PubMed]
  10. Vezza, T.; Algieri, F.; Rodriguez-Nogales, A.; Garrido-Mesa, J.; Utrilla, M.P.; Talhaoui, N.; Gomez-Caravaca, A.M.; Segura-Carretero, A.; Rodriguez-Cabezas, M.E.; Monteleone, G.; et al. Immunomodulatory properties of Olea europaea leaf extract in intestinal inflammation. Mol. Nutr. Food Res. 2017, 61, 1601066. [Google Scholar] [CrossRef] [PubMed]
  11. Wang, L.; Ma, R.; Liu, C.; Liu, H.; Zhu, R.; Guo, S.; Tang, M.; Li, Y.; Niu, J.; Fu, M.; et al. Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases. Curr. Pharm. Des. 2017, 23, 1077–1097. [Google Scholar] [CrossRef] [PubMed]
  12. Wang, H.; Chen, X.P.; Qiu, F.Z. Salviae miltiorrhizae ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats. Hepatobiliary Pancreat. Dis. Int. 2003, 2, 391–396. [Google Scholar] [PubMed]
  13. Kang, D.G.; Oh, H.; Sohn, E.J.; Hur, T.Y.; Lee, K.C.; Kim, K.J.; Kim, T.Y.; Lee, H.S. Lithospermic acid B isolated from Salvia miltiorrhiza ameliorates ischemia/reperfusion-induced renal injury in rats. Life Sci. 2004, 75, 1801–1816. [Google Scholar] [CrossRef] [PubMed]
  14. Jalalipour, M.; Yegdaneh, A.; Talebi, A.; Minaiyan, M. Salvia officinalis leaf extracts protect against acute colitis in rats. Res. Pharm. Sci. 2022, 17, 350–359. [Google Scholar] [CrossRef] [PubMed]
  15. Bonesi, M.; Loizzo, M.R.; Acquaviva, R.; Malfa, G.A.; Aiello, F.; Tundis, R. Anti-inflammatory and Antioxidant Agents from Salvia Genus (Lamiaceae): An Assessment of the Current State of Knowledge. Antiinflamm. Antiallergy Agents Med. Chem. 2017, 16, 70–86. [Google Scholar] [CrossRef]
  16. Silva, I.; Solas, J.; Pinto, R.; Mateus, V. Chronic Experimental Model of TNBS-Induced Colitis to Study Inflammatory Bowel Disease. Int. J. Mol. Sci. 2022, 23, 4739. [Google Scholar] [CrossRef] [PubMed]
  17. Delgado-Torre, M.P.; Ferreiro-Vera, C.; Priego-Capote, F.; Perez-Juan, P.M.; Luque de Castro, M.D. Comparison of accelerated methods for the extraction of phenolic compounds from different vine-shoot cultivars. J. Agric. Food Chem. 2012, 60, 3051–3060. [Google Scholar] [CrossRef]
  18. Cadiz-Gurrea, M.L.; Pinto, D.; Delerue-Matos, C.; Rodrigues, F. Olive Fruit and Leaf Wastes as Bioactive Ingredients for Cosmetics-A Preliminary Study. Antioxidants 2021, 10, 245. [Google Scholar] [CrossRef]
  19. Ribeiro, B.; Valentao, P.; Baptista, P.; Seabra, R.M.; Andrade, P.B. Phenolic compounds, organic acids profiles and antioxidative properties of beefsteak fungus (Fistulina hepatica). Food Chem. Toxicol. 2007, 45, 1805–1813. [Google Scholar] [CrossRef]
  20. Camuesco, D.; Peran, L.; Comalada, M.; Nieto, A.; Di Stasi, L.C.; Rodriguez-Cabezas, M.E.; Concha, A.; Zarzuelo, A.; Galvez, J. Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis. Inflamm. Bowel Dis. 2005, 11, 265–271. [Google Scholar] [CrossRef]
  21. Krawisz, J.E.; Sharon, P.; Stenson, W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984, 87, 1344–1350. [Google Scholar] [CrossRef]
  22. Anderson, M.E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 1985, 113, 548–555. [Google Scholar] [CrossRef]
  23. Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3, 1101–1108. [Google Scholar] [CrossRef]
  24. Cross, R.K.; Wilson, K.T. Nitric oxide in inflammatory bowel disease. Inflamm. Bowel Dis. 2003, 9, 179–189. [Google Scholar] [CrossRef]
  25. Ko, J.K.; Auyeung, K.K. Inflammatory bowel disease: Etiology, pathogenesis and current therapy. Curr. Pharm. Des. 2014, 20, 1082–1096. [Google Scholar] [CrossRef] [PubMed]
  26. Liu, S.; Zhao, W.; Lan, P.; Mou, X. The microbiome in inflammatory bowel diseases: From pathogenesis to therapy. Protein Cell 2021, 12, 331–345. [Google Scholar] [CrossRef]
  27. Cai, Z.; Wang, S.; Li, J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front. Med. 2021, 8, 765474. [Google Scholar] [CrossRef] [PubMed]
  28. Ganji-Arjenaki, M.; Rafieian-Kopaei, M. Phytotherapies in inflammatory bowel disease. J. Res. Med. Sci. 2019, 24, 42. [Google Scholar] [CrossRef]
  29. Lin, Z.; Wu, H.; Fu, Y.; Dai, S. Application of Herbaceous Medications for Inflammatory Bowel Disease as a Complementary and Alternative Therapy. Inflamm. Bowel Dis. 2019, 25, 1886–1895. [Google Scholar] [CrossRef] [PubMed]
  30. Tian, T.; Wang, Z.; Zhang, J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid. Med. Cell Longev. 2017, 2017, 4535194. [Google Scholar] [CrossRef] [PubMed]
  31. Balmus, I.M.; Ciobica, A.; Trifan, A.; Stanciu, C. The implications of oxidative stress and antioxidant therapies in Inflammatory Bowel Disease: Clinical aspects and animal models. Saudi J. Gastroenterol. 2016, 22, 3–17. [Google Scholar] [CrossRef] [PubMed]
  32. Aratani, Y. Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Arch. Biochem. Biophys. 2018, 640, 47–52. [Google Scholar] [CrossRef] [PubMed]
  33. Danese, S.; Gasbarrini, A. Chemokines in inflammatory bowel disease. J. Clin. Pathol. 2005, 58, 1025–1027. [Google Scholar] [CrossRef] [PubMed]
  34. Danese, S.; Semeraro, S.; Marini, M.; Roberto, I.; Armuzzi, A.; Papa, A.; Gasbarrini, A. Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation. Dig. Liver Dis. 2005, 37, 811–818. [Google Scholar] [CrossRef] [PubMed]
  35. Ohtsuka, Y.; Lee, J.; Stamm, D.S.; Sanderson, I.R. MIP-2 secreted by epithelial cells increases neutrophil and lymphocyte recruitment in the mouse intestine. Gut 2001, 49, 526–533. [Google Scholar] [CrossRef] [PubMed]
  36. Holmes, E.W.; Yong, S.L.; Eiznhamer, D.; Keshavarzian, A. Glutathione content of colonic mucosa: Evidence for oxidative damage in active ulcerative colitis. Dig. Dis. Sci. 1998, 43, 1088–1095. [Google Scholar] [CrossRef] [PubMed]
  37. Friedrich, M.; Pohin, M.; Powrie, F. Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. Immunity 2019, 50, 992–1006. [Google Scholar] [CrossRef]
  38. Papadakis, K.A.; Targan, S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 2000, 51, 289–298. [Google Scholar] [CrossRef]
  39. Neurath, M.F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 2014, 14, 329–342. [Google Scholar] [CrossRef]
  40. Slebioda, T.J.; Kmiec, Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediat. Inflamm. 2014, 2014, 325129. [Google Scholar] [CrossRef]
  41. da Cunha, F.M.; Duma, D.; Assreuy, J.; Buzzi, F.C.; Niero, R.; Campos, M.M.; Calixto, J.B. Caffeic acid derivatives: In vitro and in vivo anti-inflammatory properties. Free Radic. Res. 2004, 38, 1241–1253. [Google Scholar] [CrossRef] [PubMed]
  42. Vezza, T.; Rodriguez-Nogales, A.; Algieri, F.; Utrilla, M.P.; Rodriguez-Cabezas, M.E.; Galvez, J. Flavonoids in Inflammatory Bowel Disease: A Review. Nutrients 2016, 8, 211. [Google Scholar] [CrossRef] [PubMed]
  43. Xiao, Z.; Liu, W.; Mu, Y.P.; Zhang, H.; Wang, X.N.; Zhao, C.Q.; Chen, J.M.; Liu, P. Pharmacological Effects of Salvianolic Acid B Against Oxidative Damage. Front. Pharmacol. 2020, 11, 572373. [Google Scholar] [CrossRef] [PubMed]
  44. Oz, H.S.; Chen, T.; de Villiers, W.J. Green Tea Polyphenols and Sulfasalazine have Parallel Anti-Inflammatory Properties in Colitis Models. Front. Immunol. 2013, 4, 132. [Google Scholar] [CrossRef] [PubMed]
  45. Azuma, T.; Shigeshiro, M.; Kodama, M.; Tanabe, S.; Suzuki, T. Supplemental naringenin prevents intestinal barrier defects and inflammation in colitic mice. J. Nutr. 2013, 143, 827–834. [Google Scholar] [CrossRef] [PubMed]
  46. Camuesco, D.; Comalada, M.; Rodriguez-Cabezas, M.E.; Nieto, A.; Lorente, M.D.; Concha, A.; Zarzuelo, A.; Galvez, J. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br. J. Pharmacol. 2004, 143, 908–918. [Google Scholar] [CrossRef] [PubMed]
  47. Dou, W.; Zhang, J.; Ren, G.; Ding, L.; Sun, A.; Deng, C.; Wu, X.; Wei, X.; Mani, S.; Wang, Z. Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via NF-kappaB and MAPK signaling inactivation. Int. Immunopharmacol. 2014, 23, 170–178. [Google Scholar] [CrossRef]
  48. Comalada, M.; Camuesco, D.; Sierra, S.; Ballester, I.; Xaus, J.; Galvez, J.; Zarzuelo, A. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur. J. Immunol. 2005, 35, 584–592. [Google Scholar] [CrossRef]
  49. Yu, F.Y.; Huang, S.G.; Zhang, H.Y.; Ye, H.; Chi, H.G.; Zou, Y.; Lv, R.X.; Zheng, X.B. Effects of baicalin in CD4 + CD29 + T cell subsets of ulcerative colitis patients. World J. Gastroenterol. 2014, 20, 15299–15309. [Google Scholar] [CrossRef]
  50. Schreiber, S.; Rosenstiel, P.; Hampe, J.; Nikolaus, S.; Groessner, B.; Schottelius, A.; Kuhbacher, T.; Hamling, J.; Folsch, U.R.; Seegert, D. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 2002, 51, 379–385. [Google Scholar] [CrossRef]
  51. Pedersen, J.; Coskun, M.; Soendergaard, C.; Salem, M.; Nielsen, O.H. Inflammatory pathways of importance for management of inflammatory bowel disease. World J. Gastroenterol. 2014, 20, 64–77. [Google Scholar] [CrossRef]
  52. Hossen, I.; Hua, W.; Ting, L.; Mehmood, A.; Jingyi, S.; Duoxia, X.; Yanping, C.; Hongqing, W.; Zhipeng, G.; Kaiqi, Z.; et al. Phytochemicals and inflammatory bowel disease: A review. Crit. Rev. Food Sci. Nutr. 2020, 60, 1321–1345. [Google Scholar] [CrossRef] [PubMed]
  53. Lechuga, S.; Ivanov, A.I. Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms. Biochim. Biophys. Acta Mol. Cell Res. 2017, 1864, 1183–1194. [Google Scholar] [CrossRef] [PubMed]
  54. Chelakkot, C.; Ghim, J.; Ryu, S.H. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp. Mol. Med. 2018, 50, 1–9. [Google Scholar] [CrossRef]
  55. Martini, E.; Krug, S.M.; Siegmund, B.; Neurath, M.F.; Becker, C. Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease. Cell Mol. Gastroenterol. Hepatol. 2017, 4, 33–46. [Google Scholar] [CrossRef] [PubMed]
  56. Feng, P.P.; Fang, X.S.; Zhao, S.H.; Fu, J.Y.; Zhang, H.T.; Yi, Y.L.; Li, C.Y.; Jiang, C.L.; Chen, D.P. Salvianolic acid B decreases interleukin-1beta-induced colitis recurrence in mice. Chin. Med. J. 2020, 133, 1436–1444. [Google Scholar] [CrossRef] [PubMed]
  57. Einerhand, A.W.; Renes, I.B.; Makkink, M.K.; van der Sluis, M.; Buller, H.A.; Dekker, J. Role of mucins in inflammatory bowel disease: Important lessons from experimental models. Eur. J. Gastroenterol. Hepatol. 2002, 14, 757–765. [Google Scholar] [CrossRef]
  58. Van der Sluis, M.; De Koning, B.A.; De Bruijn, A.C.; Velcich, A.; Meijerink, J.P.; Van Goudoever, J.B.; Buller, H.A.; Dekker, J.; Van Seuningen, I.; Renes, I.B.; et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006, 131, 117–129. [Google Scholar] [CrossRef]
  59. Wang, Y.; Srinivasan, K.; Siddiqui, M.R.; George, S.P.; Tomar, A.; Khurana, S. A novel role for villin in intestinal epithelial cell survival and homeostasis. J. Biol. Chem. 2008, 283, 9454–9464. [Google Scholar] [CrossRef]
  60. Galvez, J.; Coelho, G.; Crespo, M.E.; Cruz, T.; Rodriguez-Cabezas, M.E.; Concha, A.; Gonzalez, M.; Zarzuelo, A. Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat. Aliment. Pharmacol. Ther. 2001, 15, 2027–2039. [Google Scholar] [CrossRef]
  61. Sanchez de Medina, F.; Galvez, J.; Romero, J.A.; Zarzuelo, A. Effect of quercitrin on acute and chronic experimental colitis in the rat. J. Pharmacol. Exp. Ther. 1996, 278, 771–779. [Google Scholar] [PubMed]
Antioxidants 12 02071 g001
Figure 1. Base peak chromatogram of S. verbenaca by UHPL-QTOF: (A) full chromatogram and (B) retention time from 8.50 to 13 min.
Figure 1. Base peak chromatogram of S. verbenaca by UHPL-QTOF: (A) full chromatogram and (B) retention time from 8.50 to 13 min.
Antioxidants 12 02071 g001
Antioxidants 12 02071 g002
Figure 2. Effects of S. verbenaca (0.1–100 μg/mL) on cell viability in CMT-93 cells. Data are expressed as means ± SEM. The experiments were performed three times.
Figure 2. Effects of S. verbenaca (0.1–100 μg/mL) on cell viability in CMT-93 cells. Data are expressed as means ± SEM. The experiments were performed three times.
Antioxidants 12 02071 g002
Antioxidants 12 02071 g003
Figure 3. Effects of S. verbenaca on (A) IL-6 and TNFα expression and release as well as (B) Mip-2, Icam-1, and Muc-2 gene expression by LPS-stimulated CMT-93 cells. Data are expressed as means ± SEM. Groups with different letters statistically differ (p < 0.05).
Figure 3. Effects of S. verbenaca on (A) IL-6 and TNFα expression and release as well as (B) Mip-2, Icam-1, and Muc-2 gene expression by LPS-stimulated CMT-93 cells. Data are expressed as means ± SEM. Groups with different letters statistically differ (p < 0.05).
Antioxidants 12 02071 g003
Antioxidants 12 02071 g004
Figure 4. Effects of different doses (10–25 mg/kg) of S. verbenaca extract and dexamethasone (DEX) (1.2 mg/kg) on (A) animal body weight, (B) macroscopic colon damages (after longitudinal opening), (C) macroscopic damage score, weight/length ratio, and (D) myeloperoxidase (MPO) activity and glutathione (GSH) content in non-colitic (NC) and TNBS-induced colitic rats. Data are expressed as means ± SEM (n = 10). Non-parametric data (score) are expressed as the median (range) and were analyzed using the Kruskal–Wallis test. Groups with different letters statistically differ (p < 0.05).
Figure 4. Effects of different doses (10–25 mg/kg) of S. verbenaca extract and dexamethasone (DEX) (1.2 mg/kg) on (A) animal body weight, (B) macroscopic colon damages (after longitudinal opening), (C) macroscopic damage score, weight/length ratio, and (D) myeloperoxidase (MPO) activity and glutathione (GSH) content in non-colitic (NC) and TNBS-induced colitic rats. Data are expressed as means ± SEM (n = 10). Non-parametric data (score) are expressed as the median (range) and were analyzed using the Kruskal–Wallis test. Groups with different letters statistically differ (p < 0.05).
Antioxidants 12 02071 g004
Antioxidants 12 02071 g005
Figure 5. Effects of different doses (10–25 mg/kg) of S. verbenaca extract and dexamethasone (DEX) (1.2 mg/kg) on colonic gene expression of Il-1β, Il-6, Il-12a, and Il-23 non-colitic (NC) and TNBS-induced colitic rats. Data are expressed as means ± SEM (n = 10). Groups with different letters statistically differ (p < 0.05).
Figure 5. Effects of different doses (10–25 mg/kg) of S. verbenaca extract and dexamethasone (DEX) (1.2 mg/kg) on colonic gene expression of Il-1β, Il-6, Il-12a, and Il-23 non-colitic (NC) and TNBS-induced colitic rats. Data are expressed as means ± SEM (n = 10). Groups with different letters statistically differ (p < 0.05).
Antioxidants 12 02071 g005
Antioxidants 12 02071 g006
Figure 6. Effects of different doses (10–25 mg/kg) of S. verbenaca extract and dexamethasone (DEX) (1.2 mg/kg) on colonic gene expression of iNos, Icam-1, Mcp-1, and Cinc-1 in non-colitic (NC) and TNBS-induced colitic rats. Data are expressed as means ± SEM (n = 10). Groups with different letters statistically differ (p < 0.05).
Figure 6. Effects of different doses (10–25 mg/kg) of S. verbenaca extract and dexamethasone (DEX) (1.2 mg/kg) on colonic gene expression of iNos, Icam-1, Mcp-1, and Cinc-1 in non-colitic (NC) and TNBS-induced colitic rats. Data are expressed as means ± SEM (n = 10). Groups with different letters statistically differ (p < 0.05).
Antioxidants 12 02071 g006
Antioxidants 12 02071 g007
Figure 7. Effects of different doses (10–25 mg/kg) of S. verbenaca extract and dexamethasone (DEX) (1.2 mg/kg) on markers of intestinal barrier integrity Muc-2, Muc-3, and Villin in non-colitic (NC) and TNBS-induced colitic rats. Data are expressed as means ± SEM (n = 10). Groups with different letters statistically differ (p < 0.05).
Figure 7. Effects of different doses (10–25 mg/kg) of S. verbenaca extract and dexamethasone (DEX) (1.2 mg/kg) on markers of intestinal barrier integrity Muc-2, Muc-3, and Villin in non-colitic (NC) and TNBS-induced colitic rats. Data are expressed as means ± SEM (n = 10). Groups with different letters statistically differ (p < 0.05).
Antioxidants 12 02071 g007
Table 1. Criteria for assessment of macroscopic colonic damage in rat TNBS-induced colitis.
Table 1. Criteria for assessment of macroscopic colonic damage in rat TNBS-induced colitis.
ScoreCriteria
0No damage
1Hyperemia, no ulcers
2Linear ulcer with no significant inflammation
3Linear ulcer with inflammation at one site
4Two or more sites of ulceration/inflammation
5Two or more major sites of ulceration and inflammation or one site of ulceration/inflammation extending along the length of the colon
6–10If damage covers along the length of the colon, the score is increased by 1 for each additional centimeter of involvement
Table 2. RT-qPCR primer sequences.
Table 2. RT-qPCR primer sequences.
GeneOrganismSequence 5′–3′Annealing T °CAccesion Number
GapdhMouse/RatFW: CCATCACCATCTTCCAGGAG
RV: CCTGCTTCACCACCTTCTTG		60NM_001289726.1
Il6MouseFW: TAGTCCTTCCTACCCCAATTTCC
RV: TTGGTCCTTAGCCACTCCTTCC		60NM_031168.2
Icam-1MouseFW: CAGTCCGCTGTGCTTTGAGA
RV: CGGAAACGAATACACGGTGAT		62NC_000075.7
Mip-2MouseFW: CAGTGAGCTGCGCTGTCCAATG
RV: CAGTTAGCCTTGCCTTTGTTCAG		57NC_000071.7
Muc2MouseFW: GCAGTCCTCAGTGGCACCTC
RV: CACCGTGGGGCTACTGGAGAG		60NC_000073.7
TnfαMouseFW: AACTAGTGGTGCCAGCCGAT
RV: CTTCACAGAGCAATGACTCC		60NM_001278601.1
Cinc-1RatFW: GGCAGGGATTCACTTCAAGA
RV: GCCATCGGTGCAATCTATCT		60NC_051349.1
Icam-1RatFW: AGGTATCCATCCATCCCACA
RV: AGTGTCTCATTGCCACGGAG		60NC_051343.1
Il1βRat FW: GATCTTTGAAGAAGAGCCCG
RV: AACTATGTCCCGACCATTGC		59NC_051338.1
Il6RatFW: CTTCCCTACTTCACAAGTC
RV: CTCCATTAGGAGAGCATTG 		60NC_051339.1
Il12aRatFW: ACGCTACCTCCTCTTCTTG
RV: ATGTCGTCCGTGGTCTTC		60NC_051337.1
Il17RatFW: TGGACTCTGAGCCGCAATGAGG
RV: GACGCATGGCGGACAATAGAGG 		60NC_051344.1
Il23RatFW: ATCCAGTGTGGTGATGGTTGTG
RV: TGTCCGAGTCCAGCAGGTG 		60NC_051342.1
iNosRatFW: AAGAGACGCACAGGCAGAGG
RV: AGCAGGCACACGCAATGAT		60NC_051345.1
Mcp-1RatFW: CACTATGCAGGTCTCTGTCACG
RV: CTGGTCACTTCTACAGAAGTGC		60NC_051345.1
Muc-2RatFW: ACCACCATTACCACCACCTCAG
RV: CGATCACCACCATTGCCACTG		60NC_051336.1
Muc-3RatFW: CACAAAGGCAAGAGTCCAGA
RV: ACTGTGCTTGGTGCTGAATG		60NC_051347.1
VillinRatFW: TGTGGAACTGGCAGGGAG
RV: GGGGTGGGTCTTGAGGTATT		59NC_051344.1
Table 3. Chemical composition of S. verbenaca extract.
Table 3. Chemical composition of S. verbenaca extract.
PeakRTMeasured m/zMolecular FormulaProposed CompoundsMain Fragments
11.01195.0538C6H12O7Gluconic acidNF
21.14133.0165C4H6O5Malic acidNF
31.28191.0226C6H8O7Citric acidNF
41.5896.9610-Sulfate NF
51.7396.9610-Sulfate NF
62.20191.0559C7H12O6Quinic acidNF
72.39395.0965C18H20O10Acetylisobiflorin179
82.74315.0723C13H16O9Gentisoyl glucoside152, 108
92.85551.1058C24H24O15Phloroscorbinol hexaacetateNF
103.19153.0188C7H6O4Dihydroxybenzoic acid109
113.38181.0502C9H10O4Dihydrocaffeic acid isomer 1135
123.67175.0608C7H12O5Isopropylmalic acidNF
134.35391.0667C18H16O10Pentahydroxy trimethoxy flavone isomer 1347, 303
144.55325.0927C15H18O8p-Coumaric acid glucoside163
154.72391.0661C18H16O10Pentahydroxy trimethoxy flavone isomer 2347, 303
165.66475.0886C22H20O12Chrysoeriol glucuronide299, 227
176.22475.1833C21H32O12Cistanoside E179, 135
186.32181.0504C9H10O4Dihydrocaffeic acid isomer 2NF
196.80179.0346C9H8O4Caffeic acid135
207.34593.1158C30H26O13O-coumaroyl orientinNF
217.65639.1199C27H28O18Quercetin glucosyl-glucuronide isomer 1463, 300
227.89405.0834C19H18O10Glucopyranosyl-trihydroxy-9H-xanthen-9-one273, 317, 387
238.12639.1157C27H28O18Quercetin glucosyl-glucuronide isomer 2299
248.20589.0826C19H26O21Unknown 1
258.28783.1637C33H36O22Quercetin glucoside derivative607, 505, 463, 300, 545
268.48353.0876C16H18O9Caffeoyl quinic acid191, 179
278.63347.0777C17H16O8Dihydroxy tetramethoxyxanthoneNF
288.78655.1288C31H28O16Acetylated flavonol glycoside isomer 1285, 461, 447
298.86329.0774C14H18O9Flavonol derivative285
308.92655.1292C31H28O16Acetylated flavonol glycoside isomer 2285, 461
318.96655.1299C31H28O16Acetylated flavonol glycoside isomer 3285, 461, 447
329.02637.1058C27H26O18Luteolin diglucuronide351, 285
339.10571.1082C27H24O14Yunnaneic acid E isomer 1197, 285, 135, 527, 241, 329, 439
349.23571.1083C27H24O14Yunnaneic acid E isomer 2197, 135, 285, 347, 527, 241, 483, 439
359.29539.1189C27H24O12Yunnaneic acid D297, 179, 197, 161, 135, 359
369.35415.1953C20H32O9Yunnaneic acid derivative 1329, 179, 161, 297
379.47597.1263C29H26O14Yunnaneic acid F197, 135, 329, 179
389.63309.0616C14H14O8Feruloylmalic acid193, 134
399.71555.1157C27H24O13Salvianolic acid K isomer 1197, 135, 329, 179
409.76585.1273C28H26O14Naringenin digalloylglucopyranoside isomer 1271
419.79585.1244C28H26O14Naringenin digalloylglucopyranoside isomer 2271
429.84585.1221C28H26O14Naringenin digalloylglucopyranoside isomer 3271
439.87461.0740C21H18O12Luteolin glucuronide285
449.95361.0938C18H18O8Crotepoxide273, 241
4510.03527.1208C26H24O12Yunnaneic acid derivative 2 isomer 1135, 197, 179, 285
4610.15719.1629C36H32O16Sagerinic acid359, 161, 197, 179
4710.24527.1198C26H24O12Yunnaneic acid derivative 2 isomer 2285, 197, 135, 241, 179, 439
4810.33717.1479C33H34O18Salvianolic acid L359, 161, 197
4910.49511.1293C26H24O11Salvianolic acid A hydrate269, 197, 135, 179
5010.58343.0924C22H16O4Unknown 2
5110.64555.1153C27H24O13Salvianolic acid K isomer 2359, 161, 135, 493, 401, 537
5210.74711.3987C37H60O13Hydroxytormentic acid derivative isomer 1503
5310.87533.1302C25H26O13Yunnaneic acid derivative 3 isomer 1197
5410.93541.1365C27H26O12Yunnaneic acid derivative 4197, 509, 135, 179
5510.95533.1315C25H26O13Yunnaneic acid derivative 3 isomer 2197
5610.99537.1053C27H22O12Lithospermic acid A295, 161, 359, 135, 197, 493
5711.06651.2319C31H40O15Martynoside175, 475
5811.17373.0936C19H18O8Methyl rosmarinate isomer 1197, 161
5911.21373.0917C19H18O8Methyl rosmarinate isomer 2135, 175, 197
6011.38711.3966C37H60O13Hydroxytormentic acid derivative isomer 2503
6111.43481.1125C25H22O10Silybin301, 283
6211.62493.1144C26H22O10Salvianolic acid A295
6311.71479.0992C25H20O10Dehydrosilybin299, 281
6411.76491.0985C26H20O10Salvianolic acid C293
6511.99327.2151C18H32O5Trihydroxyoctadecadienoic acidNF
6612.19695.4023C37H60O12Unknown 3
6712.47329.2330C18H34O5Pinellic acidNF
6812.57523.1242C27H24O11Salvianolic acid derivative135, 179, 491, 359
6912.77345.1717C20H26O5Rosmanol isomer 1NF
7013.56307.1909C18H28O4Unknown 4
7114.20345.1702C20H26O5Rosmanol isomer 2301, 283
7214.32311.2206C18H32O4Octadecenedioic acidNF
7314.74331.1918C20H28O4Carnosic acid287, 244
7414.99721.3674C34H58O16Palmitoleic-linolenicglucoside397, 277, 415, 235
7515.80293.2116C18H30O3Hydroxylinolenic acid isomer 1NF
7615.82293.2119C18H30O3Hydroxylinolenic acid isomer 2NF
7716.39295.2276C18H32O3Hydroxylinoleic acidNF
7816.68455.3168C29H44O4Diosgenin acetateNF
7917.22471.3479C30H48O4Maslinic acid isomer 1NF
8017.36471.3485C30H48O4Maslinic acid isomer 2NF
Table 4. Total phenolic content and antioxidant capacity of S. verbenaca.
Table 4. Total phenolic content and antioxidant capacity of S. verbenaca.
MethodValue
Folin–Ciocalteu (mg GAE/g d.e.)166 ± 4
FRAP (mmol eq. FeSO4/g d.e.)2.6 ± 0.1
TEAC (mmol eq. Trolox/g d.e.)0.73 ± 0.02
ORAC (mmol eq. Trolox/g d.e.)0.92 ± 0.03
GAE = gallic acid equivalents; d.e. = dry extract; eq. = equivalent.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Vezza, T.; Molina-Tijeras, J.A.; Rodríguez-Nogales, A.; Garrido-Mesa, J.; Cádiz-Gurrea, M.d.l.L.; Segura-Carretero, A.; González-Tejero, M.R.; Rodríguez-Cabezas, M.E.; Gálvez, J.; Algieri, F. The Antioxidant Properties of Salvia verbenaca Extract Contribute to Its Intestinal Antiinflammatory Effects in Experimental Colitis in Rats. Antioxidants 2023, 12, 2071. https://doi.org/10.3390/antiox12122071

AMA Style

Vezza T, Molina-Tijeras JA, Rodríguez-Nogales A, Garrido-Mesa J, Cádiz-Gurrea MdlL, Segura-Carretero A, González-Tejero MR, Rodríguez-Cabezas ME, Gálvez J, Algieri F. The Antioxidant Properties of Salvia verbenaca Extract Contribute to Its Intestinal Antiinflammatory Effects in Experimental Colitis in Rats. Antioxidants. 2023; 12(12):2071. https://doi.org/10.3390/antiox12122071

Chicago/Turabian Style

Vezza, Teresa, Jose Alberto Molina-Tijeras, Alba Rodríguez-Nogales, Jose Garrido-Mesa, María de la Luz Cádiz-Gurrea, Antonio Segura-Carretero, María Reyes González-Tejero, María Elena Rodríguez-Cabezas, Julio Gálvez, and Francesca Algieri. 2023. "The Antioxidant Properties of Salvia verbenaca Extract Contribute to Its Intestinal Antiinflammatory Effects in Experimental Colitis in Rats" Antioxidants 12, no. 12: 2071. https://doi.org/10.3390/antiox12122071

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop